SURVANTA CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. During controlled clinical trials, the most commonly reported adverse experiences were associated with the dosing procedure: Transient bradycardia 11.9% of doses; oxygen desaturation 9.8% of doses; ETT reflux, fewer than 1% of doses.

* IMS DDD Lung Surfactant Market Purchases July 1991 through June 2007. On file, Abbott Nutrition Marketing Research.